KDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury.
OBJECTIVE
The purpose of this study was to investigate if KDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury (CIA).


METHODS
In the period between January 2006 and December 2011, we identified Japanese patients who had been diagnosed with cancer and treated with cisplatin as a first-line chemotherapy at Nagoya University Hospital. The serum creatinine was used to define CIA and determine the KDIGO criteria of each patient after chemotherapy within 7 days.


RESULTS
Eighty-nine patients (5.4%) were classified as having acute kidney injury (AKI) going by the KDIGO criteria, and the numbers of patients classified into AKI stages 1, 2 and 3 were 65 (3.9%), 18 (1.1%) and 6 (0.4%), respectively. Overall survival times were significantly shorter in AKI stages 2 and 3 than in stage 1. The area under the receiver operating characteristic curve with all patients was 0.68, and that of patients who were diagnosed with cancer stage 4 was 0.80.


CONCLUSIONS
These results suggest that KDIGO criteria can be a predictor of CIA mortality in patients with different primary cancers.
Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomohiro
T
Mizuno
Waichi
W
Sato
Kazuhiro
K
Ishikawa
Hibiki
H
Shinjo
Yasuhiro
Y
Miyagawa
Yukihiro
Y
Noda
Enyu
E
Imai
Kiyofumi
K
Yamada
D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011237:Predictive Value of Tests; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D003404:Creatinine; D002945:Cisplatin